
Incyte’s promising thrombocythemia drug; Crescent Biopharma raises $200M in PIPE
Plus, news about D&D Pharmatech and Jasper Therapeutics:
Incyte’s thrombocythemia win: The company’s antibody INCA033989, which targets and reduces cells with mutant calreticulin (mutCALR), allowed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.